RNA Therapy Improves Vision in Child Blindness, hear more about recent developments in RNA Therapy at RNA Therapeutics 2019
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved the vision of LCA-affected children in a small clinical study.*
The field of RNA therapeutics has seen dramatic, positive developments in the last few years, moving towards the path of treatment for multiple conditions where the current standard of therapy is failing.
The study, published in Nature Medicine, found one patient improve from only being able to differentiate light or dark, to reading letters on an eye chart two months after the first injection.
Antisense oligonucleotides, used in the above study, were found to influence RNA processing and modulate protein expression over 20 years ago and much progress has been made translating these agents into a clinical setting.
This year’s RNA Therapeutics Conference (http://www.therapeutics-rna.com/openpr), returning to London, UK on 20th – 21st February for its 10th year running, is set to deliver in-depth presentations from senior, internationally renowned industry experts including Exicure, Roche, MHRA, Dicerna Pharmaceuticals, Accanis Biotech, Ethris, Alnylam, and many more.
Focused presentations on oligonucleotide therapies, opportunities and challenges in drug developments, and securing oligonucleotide supply include:
“Advances in Targeted Delivery of Anti-Sense Oligonucleotide Therapeutics to Pancreatic SS-Cells for Regenerative Approaches in Type 2 Diabetes”, presented by Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca.
“Delivering Therapeutic Oligonucleotides across Biobarriers: Opportunities and Challenges in Drug Development”, presented by Ekkehard Leberer, Senior Director, Sanofi-Aventis Deutschland GmbH.
“Planning for Oligonucleotide Supply: Personalized Medicine to Large Scale Markets”, presented by Hans Kistemaker, Associate Director, ProQR.
Visit the website for more information and to download the latest brochure with the full agenda and speaker line-up, as well as other exclusive content at: http://www.therapeutics-rna.com/openpr
10th Annual RNA Therapeutics Conference
20th – 21st February 2019
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
SMi Group Ltd, India House, 45 Curlew Street, London, SE1 2ND
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RNA Therapy Improves Vision in Child Blindness, hear more about recent developments in RNA Therapy at RNA Therapeutics 2019 here
News-ID: 1466387 • Views: 1263
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and
Special student rate for RNA Nanotechnology conference
Fusion Conferences and the Chairs of RNA Nanotechnology have introduced a Special Student Rate for their conference on 01-04 August 2016. The conference, to be held at Wokefield Park in Berkshire, UK, sold out earlier this month with registrations being closed off to the public, but Fusion have opened up some spaces to allow students to enjoy the conference at a discounted rate. Dr. Peixuan Guo of Ohio State University and one